Transforming Your Life After 50 Through Microdosing with Cesar Marin

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

#CathieWood #ARKG #PsychedelicStocks

Here are our Top 5 Best Psychedelic Stock Picks for 2021. For those who have watched our top 5 shroom stocks for 2020, you might notice that some stocks have stayed and others have been replaced because they have proven to be worthy of The Psychedelic Investor’s list by filling in the top 3 factors that we look at before investing in the psychedelic medicines industry, such as:
Clinical Trial Progress
Molecules & Compounds Pipeline
The Company’s war chest to sustain growth as a biotech company in a new industry

But why invest in psychedelic stocks?
Ever since last year, celebrity investors such as Kevin O’Leary and Peter Thiel decided to invest in the psychedelic/ shroom stocks industry, the industry grew from 2 or 3 companies to approximately 30 in 2021. This is probably one of the main reasons why we call this phenomenon the SHROOM BOOM!
But why do such investors seem to believe so much in the potential explosive growth of psychedelic stocks?
1. Psychedelics have been shown in many recent clinical trials to help a variety of mental health issues, from addiction, to depression to PTSD and more.
2.These psychedelic companies are attempting to disrupt the 100 billion annual industry for mental health pharmaceuticals.
3.These psychedelic compounds have the potential to help millions world wide, this also presents an amazing opportunity for early investors.
4.Smart investors might realize that rather than going all in on one company in the field, it is probably best to diversify your risk and create a Psychedelic Medicines portfolio.

So our top 5 Shroom Stock Pics for 2021 are:
5. Cybin ( CYBN on NEO & CLXPF on the OTC)
4. Numinus Wellness (LKYSF on the OTC & NUMI on the TSX)
3. Compass Pathways (CMPS on Nasdaq)
2. Atai Life Sciences – Soon to IPO on the Nasdaq
1 Mind Medicine or MindMed (MMED on NEO MNMD on Nasdaq & MMQ on FRA)
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Numinus (NUMI) : https://numinus.ca/
Link to Compass Pathways (CMPS) : https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Linke To MindMed (MMED / MNMD / MMQ) https://mindmed.co/

Timestamps:
0:00 – Intro
1:58 – Ranking criteria
3:42 – Cybin (CYBN) ( CLXPF)
6:24 – Numinus Wellness ( NUMI)
10:04 – Compass Pathways (CMPS)
13:52 – Atai Life Sciences
18:50 – MindMed ( MMED / MNMD/ MMQ )

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Clinical trials :

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPSStock

Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES

Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202

In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.

In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.

This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.

The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.

Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.

Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.

Links:
Psilocybin Study
https://www.science.org/doi/10.1126/sciadv.abh2399#F5

Psilocybin article
https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage

Ayahuasca study:
https://pubmed.ncbi.nlm.nih.gov/34822961/

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com
Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Psilocybin #DMT #Psychedelics